# How much reassurance does the record offer?

> Ipamorelin safety at Lifted Peptides — Lifted Peptides examines short-term trial safety, a separate ghrelin-agonist animal warning and the unresolved question of longer-term ipamorelin safety.

**Safety observations**

I respect a selective hormone response. I’m much harder to satisfy about safety over time.

## The perioperative observation window

In the [randomized bowel-resection trial](https://pubmed.ncbi.nlm.nih.gov/25331030/), treatment-emergent adverse events were reported in 87.5% of the ipamorelin arm and 94.8% of the placebo arm. The study reported no ipamorelin-specific safety signal in that short perioperative window.

I distrust reassurance drawn simply from the lower percentage in the treatment arm. These were adults undergoing bowel resection, observed around surgery. The result describes that setting. A claim about longer use in another population needs observations covering that use and population.

The [small healthy-volunteer study](https://pubmed.ncbi.nlm.nih.gov/10496658/) adds acute intravenous exposure and hormone-response information in healthy men. Put beside the surgical trial, it makes the narrowness of the human record quite visible. Those are valuable experiments, and I still cannot extract a settled long-term safety verdict from them.

## The related-compound rat experiment

A [preclinical cardiovascular safety study](https://pubmed.ncbi.nlm.nih.gov/25722321/) tested a different ghrelin-receptor agonist. After 28 days of oral administration, rats showed dose-dependent myocardial degeneration and necrosis—damage and death in heart muscle tissue. Ipamorelin was not the tested compound.

The [combination of measurements](https://pubmed.ncbi.nlm.nih.gov/25722321/) is instructive. Tissue examination detected injury, and the heart-type fatty-acid-binding protein FABP3 was elevated at the highest doses, while cardiac troponins were not elevated. A quiet troponin result therefore sat beside evidence of tissue damage in this particular experiment.

I treat this as a reason for demanding careful chronic safety work across the receptor class. Assigning the observed injury directly to ipamorelin would outrun the experiment. Ignoring it because the molecule differed would also throw away a relevant warning. The useful position is an unresolved ipamorelin-specific question, with the other compound and the rat model clearly identified.

## The longer-term question

A [gerontology review](https://doi.org/10.3389/fragi.2026.1790247) identifies ipamorelin among non-approved peptides lacking long-term safety data and systematic validation. Another [review of peptide safety and athletic performance](https://doi.org/10.1007/s40279-026-02437-0) emphasizes the scarcity of rigorous human safety data and the potential for serious harm.

My threshold for reassurance would require ipamorelin-specific human follow-up long enough to address sustained exposure, with meaningful clinical outcomes and careful adverse-event assessment.

The [original selectivity work](https://pubmed.ncbi.nlm.nih.gov/9849822/) remains impressive within its acute animal setting. It contributes one kind of information to the safety question. The short human record and the class-level warning contribute others. Together they leave the longer-term ipamorelin question unresolved.

---

At Lifted Peptides I follow ipamorelin from a lifted hormone signal to the practical outcomes in published research, with curiosity to spare and no medical advice to give.